corticorelin ovine triflutate (Acthrel)
corticorelin ovine triflutate is an FDA-licensed reference biologic from Ferring Pharmaceuticals Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1996
Reference approved
Reference product
Acthrel corticorelin ovine triflutate
Ferring Pharmaceuticals Inc.
- Approved
- May 23, 1996
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for corticorelin ovine triflutate, in chronological order.
Reference approval
Approval date of the reference corticorelin ovine triflutate product.
30 yr 6 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
23 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for corticorelin ovine triflutate (Acthrel)?
No 351(k) biosimilars or interchangeable biosimilars referencing corticorelin ovine triflutate are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.